cDC1 Prognostic and Predictive Role in Non-Small-Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors (LUNG-PREDICT)
Status
Conditions
Treatments
Study type
Funder types
Identifiers
Details and patient eligibility
About
The response rate of immune checkpoint inhibitors remains relatively low and the identification of the new predictive biomarkers is necessary. The rare population of cDC1 is very interesting, as its mouse counterparts is essential for the cross presentation of tumor-associated antigens, tumor immunity and response to immunotherapies. Their role in humans has not been studied. This proposal aims to study the prognostic role of cDC1 in a cohort of patients with advanced NSCLC, possibly demonstrating their positive predictive value of immune checkpoint inhibitors response.
Full description
Multicenter study aiming to collect patient's clinical data retrospectively and their histological samples prospectively.
The cohort will include:
- 30 patients PD-L1 > 50% treated with pembrolizumab in first line and having a progression free survival ≥ 3 months
- 30 patients PD-L1 > 50% treated with pembrolizumab in first line and having a progression free survival < 3 months
- 30 patients PD-L1 < 50% treated with cisplatin-based chemotherapy in first line
Sex
Ages
Volunteers
Inclusion criteria
- NSCLC diagnosis
- Advanced disease (Stage III-IV) according to the TNM 7th/8th classification
- Patients have to have performed pembrolizumab in first line if PD-L1 ≥ 50% or cisplastin-based chemotherapy if PD-L1 < 50%
- FFPE material available from diagnostic sample
Exclusion criteria
Trial design
0 participants in 2 patient groups
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal